Key result
Phosphoinositide 3-kinase (PI3K) targeted therapies for diabetic cardiomyopathy require special caution under certain clinical scenarios.
Therapies targeting PI3K in diabetic cardiomyopathy require special caution in certain clinical scenarios.
Urges caution with PI3K therapies in diabetic cardiomyopathy; leaves open optimal patient selection pending prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bi et al. (2020) studied this question. Phosphoinositide 3-kinase (PI3K) targeted therapies for diabetic cardiomyopathy require special caution under certain clinical scenarios.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: